PRDM16 Target

About ARIZ Precision Medicine

ARIZ Precision Medicine is a private, preclinical-stage biotech founded in 2018 and headquartered in Phoenix, Arizona (with operations noted in Davis, California). The company is developing a precision oncology platform that targets specific PRDM family genes using siRNA therapeutics delivered via a targeted nanotechnology system. With a recently granted broad US patent, a key collaboration with the UK's Nucleic Acid Therapy Accelerator (NATA), and a recent $110,000 angel investment, ARIZ is advancing a multi-indication pipeline focused on major solid and hematologic cancers. Its leadership team combines deep expertise in oncology, RNAi, drug development, and business, including the inventor of pegylation and a Herceptin co-inventor.

Therapeutic Areas

Other Leukemia Drugs